Walleye Capital
ACRS icon

Walleye Capital’s Aclaris Therapeutics ACRS Stock Holding History

Walleye Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-311,712
Closed -$477K – 4436
2025
Q1 		$477K Sell
311,712
-407,185
-57% -$869K ﹤0.01% 2602
2024
Q4 		$1.78M Buy
+718,897
New +$1.79M ﹤0.01% 1889
2023
Q4 		– Sell
-115,962
Closed -$794K – 4877
2023
Q3 		$794K Sell
115,962
-225,618
-66% -$1.93M ﹤0.01% 2445
2023
Q2 		$3.54M Buy
341,580
+223,656
+190% +$2.02M 0.01% 949
2023
Q1 		$954K Sell
117,924
-301,160
-72% -$3.82M 0.01% 1195
2022
Q4 		$6.6M Buy
419,084
+149,136
+55% +$2.4M 0.12% 211
2022
Q3 		$4.25M Buy
+269,948
New +$4.25M 0.08% 267
2022
Q1 		– Sell
-10,341
Closed -$150K – 2254
2021
Q4 		$150K Buy
+10,341
New +$157K ﹤0.01% 1563
2019
Q3 		– Sell
-55,000
Closed -$120K – 1851
2019
Q2 		$120K Buy
+55,000
New +$300K 0.01% 1155

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Walleye Capital's ACRS Position: Q2 2025 in Review

Walleye Capital sold out of Aclaris Therapeutics (ACRS) in Q2 2025, closing a stake of 311,712 shares — an estimated $477K sold.

Walleye Capital first reported a position in ACRS in Q2 2019 and held it in 9 quarters. The position peaked at $6.6M in Q4 2022. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2025.

  • Walleye Capital reported no remaining Aclaris Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Walleye Capital sold 311,712 Aclaris Therapeutics shares in Q2 2025, an estimated $477K.
  • Walleye Capital first reported a position in Aclaris Therapeutics in Q2 2019 and held it in 9 quarters.
  • Walleye Capital's Aclaris Therapeutics position peaked at $6.6M in Q4 2022.
  • 96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2025.

Based on Walleye Capital's 13F filing for Q2 2025, filed 13 Aug 2025.